U.S. pharma huge copyright scrapped two experimental weight loss drugs final yr—a once-everyday tablet, lotiglipron, on account of elevated liver enzymes along with a two times-every day pill, danuglipron, resulting from strong side effects—but CEO Albert Bourla has said the company